Driver who killed man gets suspended sentence
A driver who caused the death of a 74-year-old pedestrian in a crash in Bristol last year has received a suspended sentence.
Stuart Veck, 33, was driving a Peugeot 108 in Clifton on Saturday 21 December 2024 when he hit Paul Adams, who had been crossing the road, with his car.
Mr Adams was taken to hospital where he died during the early hours of Christmas Eve, police said.
Veck, of College Court, Fishponds, received an 18-week suspended prison sentence at Bristol Crown Court on Tuesday after pleading guilty to causing death by careless driving at an earlier hearing.
He also received an 18-month driving disqualification and was ordered to carry out 300 hours of unpaid work.
Emergency services had been called to the crash on Whiteladies Road shortly after 11:35 GMT on 21 December 2024.
CCTV showed Veck's car was stationary before he turned right from Whiteladies Road into Alma Road and crashed into Mr Adams.
Veck stopped immediately after the crash and during a police interview stated he had not seen him crossing the road.
More news stories for Bristol
Watch the latest Points West
Listen to the latest news for Bristol
Mr Adams' family had said in tribute after his death he would be "sorely missed".
They said he had lived in the Westbury-on-Trym area his entire life and had worked at Rolls Royce and Royal Mail before his retirement.
Dai Nicholas, the Avon and Somerset Police officer in the case, said: "Our thoughts remain with the family of Mr Adams.
"A specially trained officer has continued to provide them with support throughout our investigation.
"Stuart Veck admitted responsibility for what happened during the police interview and has today been sentenced accordingly.
"This tragic case hopefully serves as a reminder to all road users that even in traffic at low speed, just a moment's lapse in concentration can have devastating consequences."
Follow BBC Bristol on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Family's tribute to beloved husband killed in crash
Pedestrian dies three days after collision with car
Avon and Somerset Police
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday June 5, 2025, at 10:30 am-11:00 am EDT (14:30-15:00 GMT / 16:30-17:00 CET). A live video webcast of the presentation will be available to the general public and can be accessed at After the event, a recording will be available for replay for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS Benedikt Stefansson, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Rocketseed launches essential email signature guide for healthcare organizations
New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement through smart email signature management. CHARLOTTE, N.C., June 6, 2025 /PRNewswire/ -- Rocketseed, a global leader in business email signature management and marketing, has released a new comprehensive resource, Healthcare Email Signature Management: An Essential Guide. Specifically developed for hospitals, clinics, and other healthcare providers, the guide shows how professionally managed email signatures can support compliance, strengthen branding, and enhance communication across the sector, increasing engagement amongst both patients and staff. With healthcare professionals under increasing pressure to meet data protection regulations like HIPAA, maintain patient trust, promote new treatments and key services, and strengthen workplace inclusivity, this guide offers practical, actionable advice for IT leaders, marketers, and frontline staff alike to achieve these goals - all through everyday email. Helping Healthcare Providers Stay Professional, Compliant and ConnectedThe guide outlines how to design, manage and run marketing campaigns with email signatures and banners to meet specific healthcare industry challenges and maximize results. Key topics include: Best practice email signature design tips and examples for healthcare professionals, including doctors and administrators. Benefits of centralized signature management, including guaranteed brand consistency, and saving IT time through automating all staff signature updates. Importance of using HIPAA (plus ISO27001, GDPR and POPIA) compliant email signature management software to ensure patient confidentiality and data protection. Use of targeted, interactive email banners for promoting seasonal health campaigns, patient education, and new treatments and services - all illustrated with examples. Internal email banner use for HR, training, and strengthening workplace culture. Role of robust analytics and real-time reporting in measuring email signature and banner success and ROI. Rocketseed's platform is HIPAA compliant, works across all email clients (including Microsoft 365 and Google Workspace) and devices, and helps healthcare IT teams save hundreds of hours through automation and user directory synchronization. "In today's highly-regulated healthcare environment, clear and compliant communication is essential," says Damian Hamp-Adams, North America CEO at Rocketseed. "Our guide shows how email signatures - when centrally managed and professionally designed - can do more than meet HIPAA requirements. They become a trusted communication tool across the entire organization." Driving Engagement Through Data and DesignThe guide also explores how analytics and real-time reporting can optimize engagement. Healthcare organizations can track all recipient interactions with their email banners and signature content, enabling smarter campaign decisions, such as refining designs and optimizing targeting, to generate greater return on their communication efforts. "Our goal is to help healthcare providers meet compliance needs while turning every email into a powerful communication channel," adds Damian. "This guide shows that with the right tools, even email signatures can play a vital role in delivering better patient care and stronger internal communication." This new release joins Rocketseed's growing library of industry-focused resources, including essential guides for hotels & hospitality, transportation & logistics, insurance, pharmaceutical and construction industries - each tailored to the unique compliance, branding, and communication needs of their sectors. About Rocketseed Rocketseed is a leading provider of email signature management and marketing solutions, used and trusted by businesses worldwide. With tools for centralized signature control, automated updates, targeted banner campaigns, and robust analytics, Rocketseed helps organizations maintain brand consistency, drive engagement, and ensure compliance — all through their everyday email. Learn more at Jennifer 547354 View original content to download multimedia: SOURCE Rocketseed (United States) Inc
Washington Post
3 hours ago
- Washington Post
Poop at work. It's good for you!
Well+Being Poop at work. It's good for you! June 6, 2025 | 2:52 PM GMT Gastroenterologist Dr. Trisha Pasricha has some tips for whether to poop on company time (yes), whether to wait (no) and how to relax while on the job.
